Investor Presentaiton

..... Broadening and advancing our ADC presence U3-1402 (HER3-DXd) MK-2870 DS-7300 (I-DXd) DS-6000 (R-DXd) MK-1200 Collaborator Daiichi Sankyo Kelun Biotech Daiichi Sankyo Daiichi Sankyo Kelun Biotech 1 additional clinical asset Kelun Biotech Patritumab Generic Name deruxtecan Sacituzumab tirumotecan Ifinatamab deruxtecan Raludotatug deruxtecan Undisclosed Undisclosed Target HER3 TROP2 B7H3 CDH6 Claudin 18.2 Undisclosed Status Phase 31 Phase 3 Phase 2 Phase 1 Phase 1 Phase 1 Current Tumor Types² EGFRM NSCLC, Breast NSCLC, Breast ES-SCLC, Advanced Solid Tumors Ovarian Gl Tumors Undisclosed KEYNOTE-A39/ EV-3023 Data presented at ESMO from Phase 3 study evaluating KEYTRUDA in combination with enfortumab vedotin in 1L locally advanced or metastatic urothelial carcinoma 1. Planning to submit a biologics license application (BLA) in the U.S. by the end of March 2024 based on the Phase 2 HERTHENA-Lung01 data in EGFRm NSCLC that has progressed after EGFR TKI and platinum-based therapies 2. Shows tumor types currently being studied in various phases of development 3. Trial conducted in collaboration with Seagen and Astellas MERCK 21

View entire presentation